NCT06820957View on ClinicalTrials.gov

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

437

Participants

Timeline

Start Date

December 12, 2025

Primary Completion Date

July 15, 2032

Study Completion Date

July 15, 2032

Conditions
CIC-Rearranged SarcomaMetastatic Ewing SarcomaMetastatic High Grade SarcomaMetastatic Undifferentiated Round Cell SarcomaMetastatic Undifferentiated Sarcoma, Not Otherwise SpecifiedRound Cell Sarcoma With EWSR1-non-ETS FusionSarcoma With BCOR Genetic Alterations
Interventions
PROCEDURE

Biopsy Procedure

Undergo bone marrow aspiration and biopsy

PROCEDURE

Biospecimen Collection

Undergo tissue and/or blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

PROCEDURE

Echocardiography Test

Undergo echocardiography

DRUG

Etoposide

Given IV

OTHER

Fludeoxyglucose F-18

Given FDG

DRUG

Ifosfamide

Given IV

DRUG

Irinotecan Hydrochloride

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo FDG PET

OTHER

Questionnaire Administration

Ancillary studies

RADIATION

Radiation Therapy

Undergo radiation

DRUG

Regorafenib

Given PO

PROCEDURE

Surgical Procedure

Undergo surgery

DRUG

Vincristine Sulfate

Given IV

All Listed Sponsors
lead

Children's Oncology Group

NETWORK

NCT06820957 - Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body | Biotech Hunter | Biotech Hunter